TearScience, Inc.
MORRISVILE, N.C.,—August 15, 2011—TearScience, Inc., a privately-held medical device company,
today announced that it has appointed Diethart Reichardt as senior vice president of the European region
including Europe, Middle East and Africa. In this role, Reichardt will be responsible for sales, marketing,
operations and customer service teams based in the European region as well as a distributor network in
Africa and the Middle East. Reichardt will be based in Germany. TearScience’s advanced solutions are
designed to help eye care physicians treat patients suffering from evaporative dry eye disease and
Meibomian Gland Dysfunction.
Reichardt brings a wealth of sales, marketing and overall management experience to TearScience having
served in leadership positions for several global medical device and pharmaceutical eye care companies.
During his greater than 20 year career with Allergan, he built the company’s central European business
and served as regional vice president. As a global divisional head and corporate vice president of
Allergan, he was responsible for regaining global market leadership in the eye care business he managed.
Later, Reichardt was vice president and managing director international for ChromaVision Medical
Systems, a medical device company for oncologists. He was also president of Europe for Ocular
Sciences, where he built the fastest growing ophthalmic business in its segment in Europe. Most recently,
Reichardt was director of global business development for Sauflon Pharmaceuticals, where he relaunched
the business in central Europe and focused on market entry strategies for the U.S. and Japan.
“Given his extensive knowledge of the European eye care industry, Diethart is the perfect fit for
establishing and managing TearScience’s growth in Europe,” said Tim Willis, chief executive officer and
co-founder of TearScience. “Diethart has a proven track record of success in building hundred-million
dollar European businesses. We welcome him to the TearScience executive team and anticipate excellent
results.”
“TearScience’s solution is revolutionary and will cause a complete paradigm shift in how dry eye will be
managed and treated over the next few years,” said Diethart Reichardt. “Introducing a new, advanced
technology to the European market is exactly the type of challenge I was looking for. I look forward to
the opportunities and benefits this presents to patients, physicians and TearScience.”
In June, 2011, TearScience received U.S. FDA clearance to market its LipiFlow® Thermal Pulsation
medical device in the United States. The company’s LipiFlow® treatment device is designed to address a
root cause of evaporative dry eye disease, obstructed meibomian glands, which results in a lipid
deficiency of the eye’s natural tear film.
About TearScience, Inc.
Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant
clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye
sufferers worldwide, approximately 65 percent have evaporative dry eye, which is often caused by
meibomian gland dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The Tear Film
and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from
around the world, concluded that MGD is an under-estimated condition and is very likely the most
frequent cause of dry eye disease. TearScience’s integrated, in-office system enables eye care
professionals to effectively address a root cause of evaporative dry eye, obstructed meibomian glands.
For additional information, visit www.TearScience.com.
Media Contact:
Mary Hecht-Kissell
TearScience
[email protected]
+1 (919) 523-7993